Tuesday, Mar. 26, 2024 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Validated tools are needed to estimate the risk of the more than 35 million adults living with chronic kidney disease (CKD). Boehringer Ingelheim and Carelon Research have conducted the first large-scale US validation of a new AI-driven tool for CKD. This program will discuss the Klinrisk AI model's capability to predict disease progression in individuals at all stages of CKD.

Learning Objectives

• Early identification and risk stratification of chronic kidney disease (CKD) to reduce progression.
• Utilization of an AI-driven tool, to predict CKD disease progression in adults at all stages of the disease.
• The benefits of individualized, risk-based care for patients and health systems, including helping to:
  • Prevent CKD progression.
  • Prevent heart failure hospitalizations.
  • Reduce care costs.
  • Improve quality of life.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.